Zollinger‑Ellison Syndrome (Gastrinoma) – Malignant
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop, most often in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.
When a gastrinoma is malignant—meaning it has invaded surrounding tissues or metastasized to distant sites—the condition becomes far more serious, requiring aggressive treatment and close follow‑up.
- Prevalence: Gastrinomas are the most common functional neuroendocrine tumors of the pancreas, accounting for ~20–30 % of all pancreatic neuroendocrine tumors. The overall incidence of ZES is roughly 0.1–1 per million people per year.[1] Mayo Clinic
- Age & Sex: Median age at diagnosis is 45–55 years; both men and women are affected equally.[2] NIH
- Association with MEN‑1: About 20‑25 % of patients have multiple endocrine neoplasia type 1 (MEN‑1), a hereditary syndrome that predisposes to multiple endocrine tumors.[3] WHO
Symptoms
Symptoms result from chronic acid overproduction and from the tumor itself. They may be subtle at first and can mimic common gastrointestinal disorders, which often leads to delayed diagnosis.
Gastro‑intestinal (acid‑related) symptoms
- Recurrent or refractory peptic ulcers: Ulcers often occur in atypical locations (duodenum distal to the bulb, jejunum) and may not heal with standard therapy.
- Abdominal pain: Cramping or burning pain that worsens after meals.
- Diarrhea: Stools are often watery, sometimes fatty (steatorrhea) due to acid‑induced inactivation of pancreatic enzymes.
- Heartburn / gastro‑esophageal reflux disease (GERD): Excess acid can irritate the esophagus.
- Nausea & vomiting: Particularly after large meals.
Systemic / tumor‑related symptoms
- Weight loss: Due to malabsorption and decreased appetite.
- Fatigue: From anemia (chronic blood loss) or nutritional deficiencies.
- Flushing or skin changes: Rare but can occur if the tumor secretes other hormones.
- Abdominal mass: In advanced disease a palpable mass may be felt.
Signs of metastatic disease
- New onset bone pain (common site of metastasis).
- Jaundice if liver metastases obstruct bile flow.
- Persistent cough or shortness of breath with lung involvement.
Causes and Risk Factors
Most gastrinomas are sporadic, but several identifiable risk factors exist.
Genetic factors
- Multiple Endocrine Neoplasia type 1 (MEN‑1): Inherited mutation of the MEN1 tumor‑suppressor gene. Up to 30 % of ZES patients have MEN‑1.
- Familial Gastrinoma Syndrome: Very rare autosomal‑dominant inheritance without other MEN‑1 features.
Environmental / lifestyle factors
- No strong links to diet, smoking, or alcohol have been established, though chronic Helicobacter pylori infection can exacerbate ulcer formation.
Demographic risk
- Middle‑aged adults (40‑60 years) are most commonly affected.
- Both sexes are equally represented.
Diagnosis
Because ZES mimics common ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory, multiple, or located beyond the duodenum.
Biochemical testing
- Fasting serum gastrin level: Levels > 1000 pg/mL are highly suggestive; values 2–10 times the upper limit of normal with a gastric pH < 2 support the diagnosis.[4] Cleveland Clinic
- Secretin stimulation test: Administration of secretin paradoxically raises gastrin > 120 pg/mL in ZES, distinguishing it from other causes of hypergastrinemia.
Imaging studies
- Multiphasic contrast‑enhanced CT or MRI: First‑line for locating primary tumor and assessing metastasis.
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially small duodenal lesions.
- Endoscopic ultrasound (EUS): Provides detailed images of pancreatic/duodenal lesions and allows fine‑needle aspiration for histology.
Histopathology
Biopsy (usually via EUS‑guided FNA) confirms neuroendocrine differentiation (chromogranin A, synaptophysin positive) and provides Ki‑67 proliferative index, which helps grade the tumor (G1‑G3). Malignant disease is defined by local invasion, lymph node involvement, or distant metastases.
Additional work‑up
- Bone scan or PET if bone pain is present.
- Liver function tests and alkaline phosphatase for hepatic involvement.
- Genetic testing for MEN‑1 when a hereditary pattern is suspected.
Treatment Options
Management combines control of acid hypersecretion, removal or reduction of tumor burden, and surveillance for recurrence or metastasis.
Medical therapy – controlling acid
- Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often exceed the usual gastro‑reflux range (e.g., omeprazole 60–120 mg daily) and must be titrated to symptom control and serum gastrin monitoring.[5] Mayo Clinic
- Histamine‑2 receptor antagonists (H2RAs): May be added for breakthrough symptoms, but PPIs are superior.
Surgical options
- Curative resection: For localized tumors, enucleation or pancreaticoduodenectomy (Whipple) achieves the best long‑term control.
- Debulking surgery: In metastatic disease, removal of > 90 % of tumor burden can improve symptom control and survival.
- Enucleation of duodenal gastrinomas: Preferred when the tumor is < 2 cm and not invading the pancreas.
Systemic therapies for malignant disease
- Somatostatin analogues (SSA): Octreotide or lanreotide bind somatostatin receptors, suppress gastrin release, and may stabilize tumor growth.[6] NCCN Guidelines
- Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive, unresectable pancreatic neuroendocrine tumors.
- Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive cells and can induce tumor shrinkage.
- Chemotherapy: Reserved for high‑grade (G3) tumors; regimens often include streptozocin/5‑FU or temozolomide/capecitabine.
Management of metastases
- Hepatic arterial embolization or radiofrequency ablation for liver lesions.
- Bisphosphonates or denosumab for bone metastases to reduce skeletal‑related events.
Lifestyle & supportive care
- Small, frequent meals to lessen acid spikes.
- Avoidance of NSAIDs, aspirin, and other ulcer‑promoting drugs.
- Maintain adequate calcium/vitamin D intake if on PPIs long‑term.
Living with Zollinger‑Ellison Syndrome (gastrinoma) – Malignant
Even with aggressive treatment, ZES often requires lifelong management.
Daily medication adherence
- Take PPIs exactly as prescribed; never skip doses.
- Keep a medication diary and set alarms to avoid missed doses.
Nutrition
- Consume a low‑fat, low‑acid diet (avoid citrus, tomato sauce, carbonated beverages).
- Include protein‑rich foods and complex carbohydrates to counteract malabsorption.
- Consider a dietitian referral for individualized meal planning.
Monitoring & follow‑up
- Serum gastrin and chromogranin A levels every 3–6 months.
- Imaging (CT/MRI or ^68Ga‑DOTATATE PET) at least annually, or sooner if symptoms change.
- Bone density testing if on long‑term PPIs or if metastases involve bone.
Psychosocial aspects
- Join support groups for neuroendocrine tumor patients (e.g., NET Connect).
- Address anxiety or depression with counseling; chronic illness can affect mental health.
Vaccinations & preventive health
- Influenza and COVID‑19 vaccines are recommended, especially if immunosuppressive therapies are used.
- H. pylori testing and eradication if positive, to reduce ulcer burden.
Prevention
Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced in susceptible individuals:
- Genetic counseling: Families with MEN‑1 should undergo testing and routine surveillance for pancreatic lesions.
- H. pylori eradication: Treating infection lowers overall ulcer risk, which may lessen the clinical impact of early hypergastrinemia.
- Avoid chronic NSAID or high‑dose aspirin use: These agents aggravate ulcer formation.
Complications
If untreated or inadequately controlled, ZES can lead to serious, life‑threatening problems:
- Perforated ulcer: Can cause peritonitis and requires emergency surgery.
- Upper gastrointestinal bleeding: From erosive ulcers; may necessitate endoscopic hemostasis or transfusion.
- Severe malnutrition: Chronic diarrhea and acid inactivation of pancreatic enzymes cause weight loss, electrolyte disturbances, and vitamin deficiencies.
- Gastric outlet obstruction: From ulcer scarring.
- Metastatic disease progression: Liver, lymph node, bone, or lung metastases can impair organ function and shorten survival.
- Renal stones or nephrocalcinosis: Chronic acid load can alter calcium metabolism.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with medication.
- Vomiting of blood (bright red or coffee‑ground appearance) or black, tarry stools.
- Signs of a perforated ulcer – sudden intense pain, abdominal rigidity, fever.
- Profound weakness, dizziness, or fainting (possible severe bleeding or electrolyte imbalance).
- New or worsening shortness of breath combined with chest pain (possible pulmonary embolism from metastasis).
- Unexplained high fever with chills (infection of an ulcer or tumor necrosis).
References:
- Mayo Clinic. Zollinger‑Ellison syndrome. Link. Accessed May 2024.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Gastrinoma. Link. 2023.
- World Health Organization. Neuroendocrine Tumours. WHO Classification, 5th Edition, 2022. Link.
- Cleveland Clinic. Diagnosis of Zollinger‑Ellison syndrome. Link. 2024.
- Mayo Clinic. Proton pump inhibitor therapy for ZES. Link. 2024.
- National Comprehensive Cancer Network (NCCN). Neuroendocrine and Pancreatic Tumors Guidelines, Version 2.2024. Link.